NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating potential legal claims against the Board of Directors of ViroPharma Incorporated ("ViroPharma" or the "Company") (Nasdaq: VPHM) concerning the proposed acquisition of the Company by Shire plc ("Shire") in a transaction valued at about $4.2 Billion. Under the terms of the agreement, public shareholders of ViroPharma will receive $50.00 per share in cash for each share of ViroPharma they own. If you own shares of ViroPharma and want more information about the merger investigation, please contact George Pressly, Esq. at 1(800) 631-6234 or email George at AskGeorge@morgansecuritieslaw.com. Our investigation concerns possible breaches of fiduciary duty and other violations of law byViroPharma's Board of Directors for not acting in the best interest of the Company's shareholders in connection with the sale process. Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." Attorney advertising. Prior results do not guarantee a similar outcome. Contact: Morgan & Morgan Peter Safirstein, Esq.28 West 44 th StreetSuite 2001 New York, NY 100361-800-631-6234 email@example.com SOURCE Morgan & Morgan
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.